- Profile
Professor Mark Hull
- Position: Professor of Molecular Gastroenterology
- Areas of expertise: Colorectal cancer prevention; chemoprevention; nutrition; obesity-related cancer risk
- Email: M.A.Hull@leeds.ac.uk
- Phone: +44(0)113 343 8650
- Location: Wellcome Trust Brenner, St James’ University
- Website: Twitter | ORCID
Profile
Professor Mark Hull PhD FRCP is a Clinician Scientist and Consultant Gastroenterologist with a research interest in the molecular basis of colorectal carcinogenesis and colorectal cancer prevention. He trained in Biochemistry at the University of Cambridge and Medicine at the University of Oxford. His PhD studies investigated the cell biology of gastric ulcer healing at the University of Nottingham. He has previously been awarded MRC Clinician Scientist and Senior Clinical Fellowships. He has been awarded the Linacre Medal by the Royal College of Physicians of London and the President’s Medal by the British Society of Gastroenterology. He is a NIHR Senior Investigator.
Research interests
Professor Hull's laboratory uses the full spectrum of translational cancer research methodologies from basic molecular and cell biology through to Phase II biomarker clinical studies and Phase III randomised controlled trials. The broad theme of his research is identification and characterisation of molecular mechanisms of colorectal carcinogenesis that can be utilised as targets for prevention and treatment of colorectal cancer. He studies two main areas of cancer prevention: chemoprevention and lifestyle modification (obesity). The current main focus of the work is characterisation of the anti-colorectal cancer activity of the natural omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA). He was Chief Investigator of the seAFOod Polyp Prevention Trial and the EMT trial and currently leads the EMT2 trial of EPA treatment for patients with colorectal cancer liver metastasis (NCT03428477). He has a longstanding focus on fatty acid metabolism and signalling as a target for cancer prevention and treatment. Another main area of interest is the link between obesity, weight loss and colorectal cancer risk.
He collaborates closely with Dr's Milene Volpato and Louise Coletta in Leeds, as well as the Leeds Clinical Trials Unit. External collaborations include Dr Paul Loadman (Institute of Cancer Therapeutics, University of Bradford), Professor Colin Rees (Newcastle University), Professor Eva Morris (Oxford), and Dr Andrew Chan (MGH, Boston). Work is currently funded by the NIHR, Yorkshire Cancer Research and US NIH. Professor Hull has previously received funding from MRC, Cancer Research UK and World Cancer Research Fund International.
Qualifications
- BA (Hons) Cantab
- BM BCh (Oxon)
- PhD (Nottingham)
- FRCP (London)
Professional memberships
- British Society of Gastroenterology
- ISSFAL
Student education
I undertake undergraduate and postgraduate clinical teaching. I lecture to Food Sciences undergraduates.
I have supervised clinical and non-clinical postgraduate research students for many years. Seventeen students completed and awarded PhD/MD.
Research groups and institutes
- Leeds Institute of Medical Research at St James's
Postgraduate research opportunities
We welcome enquiries from motivated and qualified applicants from all around the world who are interested in PhD study. Our research opportunities allow you to search for projects and scholarships.
Projects
Research outputs
Loading...My five most recent selected research outputs
Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA, Whitham D, Montgomery AA, seAFOod Collaborative Group. 2018. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. The Lancet. 2583-2594+ 392.10164 
Hull Mark A, Markar Sheraz R, Morris Eva JA. 2018. Cancer risk after bariatric surgery - is colorectal cancer a special case?. Nature reviews. Gastroenterology & hepatology. 635-654+ 15.11
Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, Spencer JA, Quirke P, Toogood GJ, Lawton CL, Dye L, Loadman PM, Hull MA. 2017. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 1974-1983+ 67.11
Hull MA, Cuthbert RJ, Ko CWS, Scott DJ, Cartwright EJ, Hawcroft G, Perry SL, Ingram N, Carr IM, Markham AF, Bonifer C, Coletta PL. 2017. Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis. Scientific Reports. 1-14+ 7.1
Cockbain AJ. 2014. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut. 1760-1768+ 63.11
My other selected research outputs
Journal articles
Manning Sarah, Hackney Eleanor, Dunneram Yashvee, Hull Mark A, Mitra Suparna, Stewart Christopher J, Louca Panayiotis, Meader Nick, Sharp Linda, Rees Colin. 2025. Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies. Alimentary Pharmacology & Therapeutics. 568-584+ 62.6
Sun G, Fenton H, Fuller H, Race AD, Mell T, Burke L, Downing A, Rees CJ, Brown LC, Loadman PM, Williams EA, Hull MA. 2025. Understanding mechanisms of colorectal cancer chemoprevention using seAFOod polyp prevention trial outcomes and its Biobank: STOP-ADENOMA synopsis (Award ID NIHR128210). NIHR Open Research.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Plasma n-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.. Cancer Epidemiology Biomarkers & Prevention. 394-404+ 34.3
Arasaradnam Ramesh P, Krishnamoorthy Ashwin, Hull Mark A, Wheatstone Peter, Kvasnik Frank, Persaud Krishna C. 2025. The Development and Optimisation of a Urinary Volatile Organic Compound Analytical Platform Using Gas Sensor Arrays for the Detection of Colorectal Cancer. Sensors. 599+ 25.3
Sun Ge, Fuller Harriett, Fenton Hayley, Race Amanda D, Downing Amy, Rees Colin J, Brown Louise C, Loadman Paul M, Williams Elizabeth A, Hull Mark A. 2025. The Relationship Between Dietary and Supplemental omega-3 Highly Unsaturated Fatty Acid Intake, Blood and Tissue omega-3 Highly Unsaturated Fatty Acid Concentrations, and Colorectal Polyp Recurrence: A Secondary Analysis of the seAFOod Polyp Prevention Trial. Journal of Nutrition. 549-558+ 155.2
Mitra Suparna, Stewart Christopher J, Nelson Andrew, Hampton James S, Masi Andrea C, Manning Sarah, Sharp Linda, Hull Mark A, Rees Colin J. 2024. Long-term stability of the faecal microbiome profile in faecal immunochemical test (FIT) samples. Gut. e8-e8+ 74.1
Volpato M, Hull M, Carr IM. 2024. GOTermViewer: Visualisation of Gene Ontology enrichment in multiple differential gene expression analyses. Bioinformatics and Biology Insights. 11779322241271550+ 18
Sun Ge, Li Yan Ning, Davies John R, Block Robert C, Kothapalli Kumar SD, Brenna J Thomas, Hull Mark A. 2024. Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n–3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial. American Journal of Clinical Nutrition. 360-368+ 120.2
Aldoori J, Zulyniak MA, Toogood GJ, Hull MA. 2024. Fish oil supplement use modifies the relationship between dietary oily fish intake and plasma omega-3 polyunsaturated fatty acid levels: An analysis of the UK Biobank. British Journal of Nutrition. 1608-1618+ 131.9
Sun G, Fuller H, Fenton H, Race AD, Downing A, Williams EA, Rees CJ, Brown LC, Loadman PM, Hull MA. 2024. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E2 synthesis and platelet activation in participants of the seAFOod polyp prevention trial. International Journal of Cancer. 873-885+ 154.5
Sun G, Davies JR, Mell T, Harland M, Saleh RMH, Race AD, Loadman PM, Williams EA, Minihane AM, Hull MA. 2024. APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trial. Prostaglandins Leukotrienes and Essential Fatty Acids. 102623+ 201
Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, Marshall H, Song M, Chan AT, Garrett WS, Yilmaz O, Drew DA, Collinson F, Cockbain AJ, Jones R, Loadman PM, Hall PS, Moriarty C, Cairns DA, Toogood GJ. 2023. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. e077427+ 13.11
Madurasinghe VW, Knapp P, Eldridge S, Collier D, Treweek S, Rick J, Graffy J, Parker A, Salisbury C, Torgerson D, Jolly K, Sidhu MS, Fife-Schaw C, Hull MA, Sprange K, Brettell E, Bhandari S, Montgomery A, Bower P. 2023. Can we achieve better trial recruitment by presenting patient information through multimedia? Meta-analysis of ‘studies within a trial’ (SWATs). BMC Medicine. 425+ 21.1
Davies JR, Mell T, Fuller H, Harland M, Saleh RNM, Race AD, Rees CJ, Brown LC, Loadman PM, Downing A, Minihane AM, Williams EA, Hull MA. 2023. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial. Cancer Prevention Research. 621-630+ 16.11
Downing A, Fenton H, Nickerson C, Loadman PM, Williams EA, Rees CJ, Brown LC, Morris EJA, Hull MA. 2023. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use. Alimentary Pharmacology and Therapeutics. 562-572+ 58.6
Fuller H, Race AD, Fenton H, Burke L, Downing A, Williams EA, Rees CJ, Brown LC, Loadman PM, Hull MA. 2023. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial. Prostaglandins, Leukotrienes and Essential Fatty Acids. 102570+ 192
Moon R, Moore JB, Hull MA, Zulyniak MA. 2022. Investigation of the association between high arachidonic acid synthesis and colorectal polyp incidence within a generally healthy UK population: a Mendelian randomisation approach. Lifestyle Genomics. 107-110+ 15.4
Birch R, Burr N, Subramanian V, Tiernan J, Hull M, Finan P, Rose A, Rutter M, Valori R, Downing A, Morris E. 2022. IBD-associated CRC epidemiology and outcomes: an English population-based study. The American Journal of Gastroenterology. 1858-1870+ 117.11
Hampton JS, Koo S, Dobson C, Stewart CJ, Neilson LJ, Montague K, Mitra S, Whelpton J, Addison C, Kelly P, Rushton S, Hull MA, Sharp L, Rees CJ. 2022. The COLO-COHORT (Colorectal Cancer Cohort) study: Protocol for a multi-centre, observational research study and development of a consent-for-contact research platform. Colorectal Disease. 1216-1226+ 24.10
Lu Liya, Koo Sara, McPherson Stuart, Hull Mark A, Rees Colin J, Sharp Linda. 2022. Systematic review and meta‐analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes. Colorectal Disease. 681-694+ 24.6
Bradley Christopher, Hee Siew Wan, Andronis Lazaros, Persaud Krishna, Hull Mark A, Todd John, Taylor-Phillips Sian, Smith Steve, Constable Rachel, Waugh Norman, Arasaradnam Ramesh P. 2022. REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study. BMJ Open. e058559+ 12.3
Aldoori Joanna, Cockbain Andrew J, Toogood Giles J, Hull Mark A. 2022. Omega-3 polyunsaturated fatty acids: moving towards precision use for prevention and treatment of colorectal cancer. Gut. 822-837+ 71.4
Nana Gael, Mitra Suparna, Watson Henry, Young Caroline, Wood Henry M, Perry Sarah L, Race Amanda D, Quirke Philip, Toogood Giles J, Loadman Paul M, Hull Mark A. 2021. Luminal Bioavailability of Orally Administered ω-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy. The Journal of nutrition. 2142-2152+ 151.8
Faluyi Olusola O, Hull Mark A, Markham Alexander F, Bonifer Constanze, Coletta P Louise. 2021. Reduction in the resident intestinal myelomonocytic cell population occurs during ApcMin/+ mouse intestinal tumorigenesis. Oncology Letters. 263+ 21.4
Hull Mark A. 2021. Nutritional prevention of colorectal cancer. Proceedings of the Nutrition Society. 1-6+ 80.1
Hull Mark A, Rees Colin J, Sharp Linda, Koo Sara. 2020. A risk-stratified approach to colorectal cancer prevention and diagnosis. Nature Reviews Gastroenterology & Hepatology. 773-780+ 17.12
Volpato M, Cummings M, Shaaban AM, Abderrahman B, Hull MA, Maximov PY, Broom BM, Hoppe R, Fan P, Brauch H, Jordan VC, Speirs V. 2020. Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer. Exploration of Targeted Anti-tumor Therapy. 355-371+ 2020.1
Volpato M, Ingram N, Perry SL, Spencer J, Race AD, Marshall C, Hutchinson JM, Nicolaou A, Loadman PM, Coletta PL, Hull MA. 2020. Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega‑3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Chemotherapy and Pharmacology. 879-880+ 87.6
Volpato M, Ingram N, Perry SL, Spencer J, Race AD, Marshall C, Hutchinson JM, Nicolaou A, Loadman PM, Coletta PL, Hull MA. 2020. Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Chemotherapy and Pharmacology. 173-184+ 87.2
Bhatt Deepak L, Hull Mark A, Song Mingyang, Van Hulle Carol, Carlsson Cindy, Chapman M John, Toth Peter P. 2020. Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements. J54-J64+ 22.Supplement_J
Masi Andrea C, Koo Sara, Lamb Christopher A, Hull Mark A, Sharp Linda, Nelson Andrew, Hampton James S, Rees Colin J, Stewart Christopher J. 2020. Using faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysis. Gut. 429-431+ 70.2
Burr Nicholas E, Lord Richard, Hull Mark A, Subramanian Venkataraman. 2019. Decreasing Risk of First and Subsequent Surgeries in Patients With Crohn's Disease in England From 1994 through 2013. Clinical Gastroenterology and Hepatology. 2042-2049.e4+ 17.10
Song Mingyang, Ou Fang‐Shu, Zemla Tyler J, Hull Mark A, Shi Qian, Limburg Paul J, Alberts Steven R, Sinicrope Frank A, Giovannucci Edward L, Van Blarigan Erin L, Meyerhardt Jeffrey A, Chan Andrew T. 2019. Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). International Journal of Cancer. 380-389+ 145.2
Hull Mark A, Sprange Kirsty, Hepburn Trish, Tan Wei, Shafayat Aisha, Rees Colin J, Clifford Gayle, Logan Richard F, Loadman Paul M, Williams Elizabeth A, Whitham Diane, Montgomery Alan A. 2019. Eicosapentaenoic acid and/or aspirin for preventing colorectal adenomas during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: the seAFOod RCT. Efficacy and Mechanism Evaluation. 1-154+ 6.4
McFarlane Michael, Bhala Neeraj, China Louise, Alrubaiy Laith, Chedgy Fergus, Disney Benjamin R, Farmer Adam D, Fogden Edward, Sadler Gareth, Hull Mark A, McLaughlin John, Ellison Howard, Solomon Julie, Brookes Matthew James. 2019. Attitudes to out-of-programme experiences, research and academic training of gastroenterology trainees between 2007 and 2016. Frontline Gastroenterology. 57+ 10.1
Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA, Whitham D, Montgomery AA, seAFOod Collaborative Group. 2018. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. The Lancet. 2583-2594+ 392.10164
Subramanian V, Burr NE, Hull MA. 2018. Reply: Opioid Toxicity in Inflammatory Bowel Disease Patients Likely Includes Direct Enterocyte Effects That Exacerbate Disease. Clinical Gastroenterology and Hepatology. 1680-1681+ 16.10
Hull Mark A, Markar Sheraz R, Morris Eva JA. 2018. Cancer risk after bariatric surgery - is colorectal cancer a special case?. Nature reviews. Gastroenterology & hepatology. 635-654+ 15.11
Volpato M, Hull MA. 2018. Omega-3 polyunsaturated fatty acids as adjuvant therapy of colorectal cancer. Cancer and Metastasis Reviews. 545-555+ 37.2-3
Aravani A, Downing A, Thomas JD, Lagergren J, Morris EJA, Hull MA. 2018. Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. Cancer Epidemiology. 99-104+ 53
Burr NE, Smith C, West R, Hull MA, Subramanian V. 2018. Increasing Prescription of Opiates and Mortality in Patients With Inflammatory Bowel Diseases in England. Clinical Gastroenterology and Hepatology. 534-541.e6+ 16.4
Nakanishi Masako, Hanley Matthew P, Zha Ruochen, Igarashi Yuichi, Hull Mark A, Mathias Gary, Sciavolino Frank, Grady James J, Rosenberg Daniel W. 2018. A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in ApcΔ14/+ mice. Carcinogenesis. 429-438+ 39.3
Lawler Mark, Alsina Deborah, Adams Richard A, Anderson Annie S, Brown Gina, Fearnhead Nicola S, Fenwick Stephen W, Halloran Stephen P, Hochhauser Daniel, Hull Mark A, Koelzer Viktor H, McNair Angus GK, Monahan Kevin J, Näthke Inke, Norton Christine, Novelli Marco R, Steele Robert JC, Thomas Anne L, Wilde Lisa M, Wilson Richard H, Tomlinson Ian. 2018. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut. 179-193+ 67.1
Lawless D, Mistry A, Wood PM, Stahlschmidt J, Arumugakani G, Hull M, Parry D, Anwar R, Carter C, Savic S. 2017. Bialellic Mutations in Tetratricopeptide Repeat Domain 7A (TTC7A) Cause Common Variable Immunodeficiency-Like Phenotype with Enteropathy. Journal of Clinical Immunology. 617-622+ 37.7
Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, Spencer JA, Quirke P, Toogood GJ, Lawton CL, Dye L, Loadman PM, Hull MA. 2017. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 1974-1983+ 67.11
Hull MA, Cuthbert RJ, Ko CWS, Scott DJ, Cartwright EJ, Hawcroft G, Perry SL, Ingram N, Carr IM, Markham AF, Bonifer C, Coletta PL. 2017. Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis. Scientific Reports. 1-14+ 7.1
Volpato M, Spencer JA, Race AD, Munarini A, Belluzzi A, Cockbain AJ, Hull MA, Loadman PM. 2017. A liquid chromatography–tandem mass spectrometry method to measure fatty acids in biological samples. Journal of Chromatography B. 125-134+ 1055–1
Tao W, Konings P, Hull MA, Adami HO, Mattsson F, Lagergren J. 2017. Colorectal Cancer Prognosis Following Obesity Surgery in a Population-Based Cohort Study. Obesity Surgery. 1233-1239+ 27.5
Burr Nick E, Hull Mark A, Subramanian Venkataraman. 2017. Folic Acid Supplementation May Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 247-253+ 51.3
Watson H, Cockbain AJ, Spencer J, Race A, Volpato M, Loadman PM, Toogood GJ, Hull MA. 2016. Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins, Leukotrienes and Essential Fatty Acids. 60-66+ 115
Walsh E, Rees CJ, Gill M, Parker CE, Bevan R, Perry SL, Bury Y, Mills S, Bradburn DM, Bramble M, Hull MA. 2016. Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?. British Journal of Cancer. 261-265+ 115.2
Burr NE, Hull MA, Subramanian V. 2016. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?. World Journal of Gastroenterology. 3679-3686+ 22.13
Volpato M, Perry SL, Marston G, Ingram N, Cockbain AJ, Burghel H, Mann J, Lowes D, Wilson E, Droop A, Randerson-Moor J, Coletta PL, Hull MA. 2016. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis. Oncotarget. 28139-28150+ 7.19
Brown Peter, Clark Tanya, Dowson Grace, Warren Lisa, Hamlin John, Hull Mark, Subramanian Venkataraman. 2016. Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn’s Disease. Journal of Crohn's and Colitis. 1144-1150+ 10.10
Hull MA, McLaughlin JT. 2015. Successful delivery of clinical gastroenterology studies in the UK. Gut. 854-856+ 64.5
Scaioli Eleonora, Cardamone Carla, Liverani Elisa, Munarini Alessandra, Hull Mark A, Belluzzi Andrea. 2015. The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid. BioMed Research International. 360825+ 2015.1
Cockbain AJ. 2014. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut. 1760-1768+ 63.11
Piazzi G, D'Argenio G, Prossomariti A, Lembo V, Mazzone G, Candela M, Biagi E, Brigidi P, Vitaglione P, Fogliano V, D'Angelo L, Fazio C, Munarini A, Belluzzi A, Ceccarelli C, Chieco P, Balbi T, Loadman PM, Hull MA, Romano M, Bazzoli F, Ricciardiello L. 2014. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. International Journal of Cancer. 2004-2013+ 135.9
Cockbain Andrew J, Volpato Milene, Race Amanda D, Munarini Alessandra, Fazio Chiara, Belluzzi Andrea, Loadman Paul M, Toogood Giles J, Hull Mark A. 2014. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.. Gut. 1760-1768+ 63.11
Gill MD, Bramble MG, Hull MA, Mills SJ, Morris E, Bradburn DM, Bury Y, Parker CE, Lee TJW, Rees CJ. 2014. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers. British Journal of Cancer. 2076-2081+ 111.11
Piazzi G, D'Argenio G, Prossomariti A, Lembo V, Mazzone G, Candela M, Biagi E, Brigidi P, Vitaglione P, Fogliano V, D'Angelo L, Fazio C, Munarini A, Belluzzi A, Ceccarelli C, Chieco P, Balbi T, Loadman PM, Hull MA, Romano M, Bazzoli F, Ricciardiello L. 2014. OC.10.1 EICOSAPENTAENOIC ACID-FREE FATTY ACID PREVENTS AND SUPPRESSES COLONIC TUMOURS IN COLITIS-ASSOCIATED COLORECTAL CANCER. Digestive and Liver Disease. s24+ 46
Verghese Eldo Thomas, Drury Ruth, Green Caroline, Holliday Deborah, Lu Xiaomei, Nash Claire, Speirs Valerie, Thorne James, Thygesen Helene, Zougman Alexandre, Hull Mark A, Hanby Andrew M, Hughes Thomas A. 2014. Role of miR-26b in carcinoma-associated fibroblasts and effect on migration and invasion of breast cancer epithelial cells. The Lancet. s103+ 383
Kant P, Perry SL, Dexter SP, Race AD, Loadman PM, Hull MA. 2014. Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass. Obesity. 202-210+ 22.1
Hull Mark, Lagergren Jesper. 2014. Obesity and colorectal cancer.. Gut. 205+ 63.1
Kant Prashant, Perry Sarah L, Dexter Simon P, Race Amanda D, Loadman Paul M, Hull Mark A. 2014. Mucosal biomarkers of colorectal cancer risk do not increase at 6 months following sleeve gastrectomy, unlike gastric bypass.. Obesity (Silver Spring). 202-210+ 22.1
Derogar Maryam, Hull Mark A, Kant Prashant, Östlund Magdalena, Lu Yunxia, Lagergren Jesper. 2013. Increased risk of colorectal cancer after obesity surgery.. Ann Surg. 983-988+ 258.6
Verghese Eldo T, Drury Ruth, Green Caroline A, Holliday Deborah L, Lu Xiaomei, Nash Claire, Speirs Valerie, Thorne James L, Thygesen Helene H, Zougman Alexandre, Hull Mark A, Hanby Andrew M, Hughes Thomas A. 2013. MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion.. J Pathol. 388-399+ 231.3
Ingram Nicola, Northwood Emma L, Perry Sarah L, Marston Gemma, Snowden Helen, Taylor John C, Scott Nigel, Bishop D Timothy, Coletta P Louise, Hull Mark A. 2013. Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observations.. Carcinogenesis. 2341-2349+ 34.10
Burr N, Hull MA. 2013. Commentary: non-haemodynamic effects of beta-blockers in cirrhosis - more than meets the eye? Authors' reply. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 653-654+ 38.6
Burr N, Hull MA. 2013. Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer.. Aliment Pharmacol Ther. 653-654+ 38.6
Hull MA, Sandell AC, Montgomery AA, Logan RFA, Clifford GM, Rees CJ, Loadman PM, Whitham D. 2013. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): Study protocol for a randomized controlled trial. Trials. 237+ 14.1
Young Alastair L, Chalmers Claire R, Hawcroft Gillian, Perry Sarah L, Treanor Darren, Toogood Giles J, Jones Pamela F, Hull Mark A. 2013. Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases.. BMC Cancer. 92+ 13.1
Kant P, Fazakerley R, Hull MA. 2013. Faecal calprotectin levels before and after weight loss in obese and overweight subjects. International Journal of Obesity. 317-319+ 37.2
Hull MA. 2013. Nutritional agents with anti-lnflammatory properties in chemoprevention of colorectal neoplasia. Recent Results in Cancer Research. 143-156+ 191
Hull Mark A. 2013. Nutritional agents with anti-inflammatory properties in chemoprevention of colorectal neoplasia.. Recent Results Cancer Res. 143-156+ 191
Hawcroft G, Volpato M, Marston G, Ingram N, Perry SL, Cockbain AJ, Race AD, Munarini A, Belluzzi A, Loadman PM, Coletta PL, Hull MA. 2012. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.. Br J Pharmacol. 1724-1737+ 166.5
Tomlinson Darren C, Baxter Euan W, Loadman Paul M, Hull Mark A, Knowles Margaret A. 2012. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.. PLoS One. e38972+ 7.6
Lee TJW, Hull MA, Rajasekhar PT, Clifford GM, Ritchie M, James P, McNally RJQ, Rutter MD, Rees CJ. 2012. Aspirin users attending for nhs bowel cancer screening have less colorectal neoplasia: Chemoprevention or false-positive faecal occult blood testing?. Digestion. 278-281+ 85.4
Hull Mark A, Yiannakou Yan, Gower Jonathan, Ryder Stephen D, Bloom Stuart L, Rees Colin R. 2012. Getting involved in clinical trials research in the UK: how can Clinical Research Networks help?. Frontline Gastroenterology. 66+ 3.2
Kant P, Fazakerley R, Hull MA. 2012. Faecal calprotectin levels before and after weight loss in obese and overweight subjects.. Int J Obes (Lond). 317-319+ 37.2
Abdelrahman Mostafa A, Marston Gemma, Hull Mark A, Markham Alexander F, Jones Pamela F, Evans J Anthony, Coletta P Louise. 2012. High-frequency ultrasound for in vivo measurement of colon wall thickness in mice.. Ultrasound Med Biol. 432-442+ 38.3
Chan Andrew T, Arber Nadir, Burn John, Chia Whay Kuang, Elwood Peter, Hull Mark A, Logan Richard F, Rothwell Peter M, Schroer Karsten, Baron John A. 2012. Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview. CANCER PREVENTION RESEARCH. 164-178+ 5.2
Marsh Lorraine, Coletta P Louise, Hull Mark A, Selby Peter J, Carding Simon R. 2012. Altered intestinal epithelium-associated lymphocyte repertoires and function in ApcMin/+ mice.. Int J Oncol. 243-250+ 40.1
Cockbain AJ, Toogood GJ, Hull MA. 2012. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer.. Gut. 135-149+ 61.1
Hull Mark A. 2011. Omega-3 polyunsaturated fatty acids.. Best Pract Res Clin Gastroenterol. 547-554+ 25.4-5
Kant Prashant, Sainsbury Anita, Reed Karen R, Pollard Stephen G, Scott Nigel, Clarke Alan R, Coletta P Louise, Hull Mark A. 2011. Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for long-term neoplastic risk following RYGB.. Gut. 893-901+ 60.7
Marston Gemma, Jones Pam F, Evans John A, Hull Mark A, Markham Alex F, Coletta Patricia L. 2011. Abstract 1572: Characterising the tumor vasculature in vivo in mouse models of colorectal cancer using contrast enhanced high-frequency ultrasound. Cancer Research. 1572-1572+ 71.8_Supplement
Kant Prashant, Hull Mark A. 2011. Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer.. Nat Rev Gastroenterol Hepatol. 224-238+ 8.4
Nicholson Brian D, Hyland Rachel, Rembacken Bjorn J, Denyer Mark, Hull Mark A, Tolan Damian JM. 2011. Colonoscopy for colonic wall thickening at computed tomography: a worthwhile pursuit?. Surg Endosc. 2586-2591+ 25.8
West Nicholas J, Clark Susan K, Phillips Robin KS, Hutchinson John M, Leicester Roger J, Belluzzi Andrea, Hull Mark A. 2010. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.. Gut. 918-925+ 59.7
Young Alastair, Hawcroft Gillian, Chalmers Ritchie, Toogood Giles, Hull Mark. 2010. T1191 Intra-Tumoral Variability in Prostaglandin E2 Levels in Human Colorectal Cancer Liver Metastases is Associated With Differences in NAD+ Levels and Expression of NAD+-Dependent 15-Prostaglandin Dehydrogenase. Gastroenterology. s-508+ 138.5
Ingram Nicola, Perry Sarah L, Scott Nigel, Coletta Louise, Hull Mark. 2010. S1679 Loss of Interleukin-4 Receptor α Function Drives Initiation, but Not Progression, of Azoxymethane-Induced Colorectal Carcinogenesis in BALB/C Mice. Gastroenterology. s-252+ 138.5
Hawcroft Gillian, Loadman Paul M, Belluzzi Andrea, Hull Mark A. 2010. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.. Neoplasia. 618-627+ 12.8
Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA. 2009. Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.. Eur J Cancer. 1654-1663+ 45.9
Sainsbury A, Goodlad RA, Perry SL, Pollard SG, Robins GG, Hull MA. 2008. Increased colorectal epithelial cell proliferation and crypt fission associated with obesity and Roux-en-Y gastric bypass. CANCER EPIDEM BIOMAR. 1401-1410+ 17.6
Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin PJ, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. 2008. Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. ANN RHEUM DIS. 750-757+ 67.6
Ko CWS, Cuthbert RJ, Orsi NM, Brooke DA, Perry SL, Markham AF, Coletta PL, Hull MA. 2008. Lack of interleukin-4 receptor alpha chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice.. J Pathol. 603-609+ 214.5
Hull MA. 2008. Bile acids and colorectal cancer. Issues in Toxicology. 84-99+
Hull MA. 2008. Molecular pathways leading to cancer as a basis for preventive strategies. Current Colorectal Cancer Reports. 43-47+ 4.1
Mistry N, Ford AC, Hull MA, McPherson S. 2007. Electronic Clinical Challenges and Images in GI.. Gastroenterology. e3-e4+ 133.4
Chalmers CR, Fenwick SW, Toogood GJ, Hull MA. 2006. Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. Angiogenesis. 193-200+ 9.4
Mears R, Coletta PL, Hull MA, Selby PJ, Carding SR. 2005. Intestinal lymphocytes and tumour development in MIN mice. IMMUNOLOGY. 36-36+ 116
Wilson Jonathan M, Coletta P Louise, Cuthbert Richard J, Scott Nigel, MacLennan Kenneth, Hawcroft Gillian, Leng Lin, Lubetsky Jodi B, Jin Kai K, Lolis Elias, Medina Francisco, Brieva Jose A, Poulsom Richard, Markham Alexander F, Bucala Richard, Hull Mark A. 2005. Macrophage migration inhibitory factor promotes intestinal tumorigenesis.. Gastroenterology. 1485-1503+ 129.5
Hull MA. 2005. Cyclooxygenase-2: How good is it as a target for cancer chemoprevention?. European Journal of Cancer. 1854-1863+ 41.13
Hull MA, Ko SCW, Hawcroft G. 2004. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer?. Molecular Cancer Therapeutics. 1031-1039+ 3.8
Hawcroft G, Gardner SH, Hull MA. 2004. Expression of prostaglandin D(2) receptors DP1 and DP2 by human colorectal cancer cells. Cancer Letters. 81-84+ 210.1
Coletta PL, Muller AM, Jones EA, Muhl B, Holwell S, Clarke D, Meade JL, Cook GP, Hawcroft G, Ponchel F, Lam WK, MacLennan KA, Hull MA, Bonifer C, Markham AF. 2004. Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood. 1050-1058+ 103.3
Sonwalkar SA, James RM, Ahmad T, Zhang L, Verbeke CS, Barnard DL, Jewell DP, Hull MA. 2003. Fulminant Crohn's colitis after allogeneic stem cell transplantation. GUT. 1518-1521+ 52.10
Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. 2003. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. GASTROENTEROLOGY. 716-729+ 125.3
Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. 2003. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 716-729+ 125.3
Hawcroft G, Gardner SH, Hull MA. 2003. Activation of peroxisome proliferator-activated receptor gamma does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells. J PHARMACOL EXP THER. 632-637+ 305.2
Wilson JM, Scott N, Guillou PJ, Markham AF, Coletta PL, Hull MA. 2003. The Role of Macrophage Migration Inhibitory Factor in Intestinal Tumorigenesis. Clinical Science. 23p-24p+ 104.s49
Hull MA, Gardner SH, Hawcroft G. 2003. Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treatment Reviews. 309-320+ 29.4
Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. 2002. Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. Journal of Pathology. 435-441+ 198.4
Ko SC, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA. 2002. Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. ONCOGENE. 7175-7186+ 21.47
Chapple Keith S, Scott Nigel, Guillou Pierre J, Coletta P Louise, Hull Mark A. 2002. Analysis of cyclooxygenase expression in human colorectal adenomas.. Dis Colon Rectum. 1316-1324+ 45.10
Skelly RH, Kupfer RM, Metcalfe ME, Allison SP, Holt M, Hull MA, Rawlings JK. 2002. Percutaneous endoscopic gastrostomy (PEG): change in practice since 1988. Clinical Nutrition. 389-394+ 21.5
Mahadeva S, Linch M, Hull MA. 2002. Variable use of endoscopic haemostasis in the management of bleeding peptic ulcers.. Postgrad Med J. 347-351+ 78.920
Donnellan CF, Dass S, Dunn F, Hull MA. 2002. Warfarin anti-coagulation control in patients taking proton pump inhibitors. GUT. A65-A66+ 50
Ko CWS, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA. 2002. Paracrine COX-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells.. GUT. A35-A36+ 50
Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. 2002. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. CARCINOGENESIS. 107-114+ 23.1
Hawcroft Gillian, D'Amico Mark, Albanese Chris, Pestell Richard G, Hull Mark A. 2001. Indomethacin treatment is associated with differential expression of β-catenin/TCF target genes in human sporadic colorectal cancer cells. Gastroenterology. a661+ 120.5
Ko SC, Hull MA. 2001. In vitro models of cyclooxygenase-2-positive macrophage-epithelial cell interactions during intestinal tumorigenesis. GASTROENTEROLOGY. A169-A169+ 120.5
Hawcroft G, D'Amico M, Albanese C, Pestell RG, Hull MA. 2001. Indomethacin treatment is associated with differential expression of beta-catenin/TCF target genes in human sporadic colorectal cancer cells.. GASTROENTEROLOGY. A661-A661+ 120.5
Chapple KS, Scott N, Guillou PJ, Coletta PL, Hull MA. 2001. Cyclooxygenase-2 and angiogenesis in human sporadic colorectal adenomas. GUT. A71-A71+ 48
Scott DJ, Hull MA, Cartwright EJ, Lam WK, Tisbury A, Poulsom R, Markham AF, Bonifer C, Coletta PL. 2001. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the ApcMin/+ mouse. GASTROENTEROLOGY. 889-899+ 121.4
Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GJ, Lodge JJPA. 2000. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clinical and Experimental Metastasis. 21-27+ 18.1
Smith ML, Hawcroft G, Hull MA. 2000. The effect of non-steroidal anti-inflammatory drugs in human colorectal cancer cells: evidence of different mechanisms of action. European Journal of Cancer. 664-674+ 36.5
Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor ACJ, Guillou PJ, Markham AF, Coletta PL, Hull MA. 2000. Localization of Cyclooxygenase-2 in human sporadic colorectal adenomas. American Journal of Pathology. 545-553+ 156.2
Peatt N, Hull MA. 2000. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. European Journal of Cancer. 664-674+ 36
Hull MA, Chapple KS, Coletta PL, Poulsom R. 2000. COX-2 in murine intestinal tumors [letter]. Gastroenterology. 600-602+ 119.2
Hull MA, Langman M. 2000. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. pp.154+ 47
Hull MA, Thomson JL, Hawkey CJ. 1999. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells.. Gut. 529-536+ 45.4
Duggan AE, Stack W, Hull MA, Knifton A, Crome R, Weber C, Bishop A, Polak J. 1999. Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist.. Alimentary Pharmacology and Therapeutics. 631-635+ 13.5
Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, Coletta PL. 1999. Cyclooxigenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. British Journal of Cancer. 1399-1405+ 79.9-10
Hull MA, Brough JL, Powe DG, Carter GI, Jenkins D. 1998. Expression of basic fibroblast growth factor in intact and ulcerated human gastric mucosa.. Gut. 525-536+ 43.4
Hull MA, Barton K, Filipowicz B, Vautier G. 1997. Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration [see comments].. Gut. 204-210+ 40.2
Hussaini SH, Hull MA. 1997. Adding heat probe treatment to adrenaline injection for spurting haemorrhage of peptic ulcers. Injection of adrenaline and human thrombin is best option [letter; comment].. British Medical Journal. 1016+ 315.7114
Hull MA, Hewett PW. 1996. Isolation and culture of human gastric endothelial cells.. Gastroenterology. 1230-1240+ 111.5
Conference papers
Burr Nicholas, Valori Roland, Subramanian Venkataraman, Hull Mark, Shelton Jon, Pearson Clare, Smith Andy, Morris Eva, Rutter Matthew. 2018. POST-COLONOSCOPY COLORECTAL CANCER RATES IN IBD ARE HIGH AND VARY BY NHS TRUST IN ENGLAND. GUT.
Volpato M, Coletta L, Hull MA. 2017. COX-2 mediates resistance to eicosapentaenoic acid in colorectal cancer cells. United European Gastroenterology Journal.
Monahan Kevin J, Alsina Deborah, Bach Simon, Buchanan James, Burn John, Clark Sue, Dawson Peter, De Souza Bianca, Din Farhat VN, Dolwani Sunil, Dunlop Malcolm G, East James, Evans D Gareth, Fearnhead Nicola, Frayling Ian M, Glynne-Jones Rob, Hill James, Houlston Richard, Hull Mark, Lalloo Fiona, Latchford Andrew, Lishman Suzy, Quirke Phil, Rees Colin, Rutter Matt, Sasieni Peter, Senapati Asha, Speake Doug, Thomas Huw, Tomlinson Ian. 2017. Urgent improvements needed to diagnose and manage Lynch syndrome. The BMJ.
Driver R, Handforth C, Kite S, Radhakrishna G, Hull M, Everett S. 2015. PTH-018 Predicting survival in palliative oesophageal stent insertion. Gut.
Driver R, Kite S, Radhakrishna G, Wright P, Hull M, Everett S. 2015. PTH-019 Palliative stenting for inoperable oesophageal cancer: results of a national survey of health professionals. Gut.
Mohammed N, Kant P, Abid F, Rotimi O, Prasad P, Hamlin J, Everett S, Rembacken B, Hull M, Subramanian V. 2015. OC-028 High definition white light endoscopy (HDWLE) versus high definition with chromoendoscopy (HDCE) in the detection of dysplasia in long standing ulcerative colitis: a randomised controlled trial. Gut.
Mohammed Noor, Kant Prashant, Abid Faisal, Rotimi Olorunda, Prasad Padmini, Hamlin John P, Everett Simon, Rembacken Bjorn, Hull Mark A, Subramanian Venkat. 2015. 446 High Definition White Light Endoscopy (Hdwle) Versus High Definition With Chromoendoscopy (Hdce) in the Detection of Dysplasia in Long Standing Ulcerative Colitis: a Randomized Controlled Trial. Gastrointestinal Endoscopy.
Burr Nicholas, Hull Mark A, Subramanian Venkat. 2015. Does Folate Supplementation Reduce Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease? A Systematic Review and Meta-Analysis. GASTROENTEROLOGY.
Gill MD, Bramble M, Hull M, Mills S, Morris E, Bradburn M, Bury Y, Parker C, Lee T, Rees C. 2013. Screen-detected colorectal cancers are associated with an improved outcome when compared with interval cancers when matched for stage. Gut.
Hutchinson JM, Volpato M, Loadman P, Nicolaou A, Hull M. 2013. PWE-163 Chemr23 and BLT1 Receptor Expression in Colorectal Cancer. Gut.
Verghese ET, Drury R, Green CA, Holliday DL, Lu X, Nash C, Speirs V, Thygesen H, Zougman A, Hull MA, Hanby AM, Hughes T. 2013. Epithelial-Stromal Cross-Talk in Breast Cancer: miR-26b Within Carcinoma-Associated Fibroblasts Regulates Epithelial Cancer Cell Migration and Invasion. JOURNAL OF PATHOLOGY.
Volpato M, Coletta L, Loadman PM, Hull MA. 2012. The Relationship Between the Anti-cancer Activity of the Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid (EPA) and Colorectal Cancer Cell Migration. EUROPEAN JOURNAL OF CANCER.
Verghese ET, Hull MA, Hanby AM, Hughes TA. 2011. Analysis of the Role of MicroRNAs within Stromal Fibroblasts in Breast Cancer. JOURNAL OF PATHOLOGY.
West NJ, Clark SK, Belluzzi A, Hutchinson JM, Hull MA, Leicester RJ, Phillips RKS. 2011. Eicosapentaenoic acid (EPA) free fatty acid reduces polyp burden in familial adenomatous polyposis (FAP): Results of a randomised, placebo-controlled trial. BRITISH JOURNAL OF SURGERY.
Kant P, Dexter S, Hull MA. 2011. RECTAL MUCOSAL BIOMARKERS OF COLORECTAL CANCER RISK ARE INCREASED IN MORBIDLY OBESE PATIENTS BUT NOT SIGNIFICANTLY DIFFERENT SIX MONTHS AFTER SLEEVE GASTRECTOMY. GUT.
Young AL, Hull MA, Toogood GJ. 2010. Hypoxia depletes NAD plus which may promote development of colorectal liver metastases. BRITISH JOURNAL OF SURGERY.
Jennings JSR, Hamlin J, Robinson PA, Hull MA, Howdle PO, Markham AF. 2010. AK155: A CANDIDATE GENE FOR INFLAMMATORY BOWEL DISEASE. GUT.
Young AL, Hawcroft G, Chalmers R, Toogood GJ, Hull MA. 2010. INTRATUMOURAL VARIABILITY IN PROSTAGLANDIN E2 LEVELS IN HUMAN COLORECTAL CANCER LIVER METASTASES IS ASSOCIATED WITH DIFFERENCES IN NAD plus LEVELS AND EXPRESSION OF NAD plus -DEPENDENT 15-PROSTAGLANDIN DEHYDROGENASE. GUT.
Ingram N, Perry SL, Scott N, Colette PL, Hull MA. 2010. LOSS OF INTERLEUKIN-4 RECEPTOR alpha FUNCTION DRIVES INITIATION, BUT NOT PROGRESSION, OF AZOXYMETHANE-INDUCED COLORECTAL CARCINOGENESIS IN BALB/C MICE. GUT.
Fogden EN, Holt A, Ellison H, Sadler G, Thompson DG, Hull MA, Brookes MJ. 2009. ATTITUDES OF UK GASTROENTEROLOGY TRAINEES TO RESEARCH AND OUT OF PROGRAMME EDUCATION. GUT.
Hawcroft G, Bretsztajn L, Hull MA. 2009. OMEGA-3 POLYUNSATURATED FATTY ACID-DERIVED PROSTAGLANDIN E3 ANTAGONISES PROSTAGLANDIN E2-EP4 RECEPTOR SIGNALLING IN HUMAN COLORECTAL CANCER CELLS. GUT.
Fogden EN, Holt A, Ellison H, Sadler G, Thompson DG, Hull MA, Brookes MJ. 2009. GENDER INEQUALITIES IN ACADEMIA IN UK GASTROENTEROLOGY TRAINEES. GUT.
Cummings M, Maraqa L, Peter MB, Shaaban AM, Hanby AM, Hull MA, Speirs V. 2008. Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer. BREAST CANCER RESEARCH.
Hull MA, Scott DJ, Cuthbert RJ, Ko S, Perry SL, Cartwright E, Bonifer C, Markham AF, Coletta L. 2008. Stromal cell cyclooxygenase-2 promotes colorectal tumorigenesis in the ApcMin/+ mouse model of familial adenomatous polyposis. GUT.
Sainsbury A, Robins GG, Goodlad R, Pollard S, Hull MA. 2007. Increased biomarkers of colorectal carcinogenesis associated with obesity and Roux-en-Y gastric bypass. GUT.
Hull MA. 2006. COX-PGE(2) signalling as a target for cancer chemoprevention. CHEMICO-BIOLOGICAL INTERACTIONS.
Hawcroft Gillian, Ko Stanley C, Hull Mark A. 2006. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells via cAMP and ERK signalling. GASTROENTEROLOGY.
Wilson JM, Cuthbert RJ, Coletta L, Hull MA. 2005. CD74 (MHC Class II invariant chain li) expression in human sporadic colorectal adenomas.. CANCER EPIDEM BIOMAR.
Wilson JM, Scott N, Coletta PL, Hull MA. 2005. Genetic deletion of macrophage migration inhibitory factor has no significant effect on intestinal tumorigenesis in the APC(MIN/+) mouse. GUT.
Wilson JM, Maclennan K, Coletta PL, Hull MA. 2004. Macrophage migration inhibitory factor (MIF) expression and pro-tumorigenic activity in human colorectal adenoma cells. GASTROENTEROLOGY.
Chalmers CR, Fenwick SW, Toogood GJ, Hull MA. 2004. Treatment with the selective COX-2 inhibitor rofecoxib is associated with increased endothelial cell apoptosis and decreased vascularity of human colorectal cancer liver metastases. GUT.
Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. 2003. A randomized double-blind, placebo-controlled trial of the effect of rofecoxib on proliferation, apoptosis and microvessel density in colorectal cancer liver metastases. BRIT J SURG.
Wilson JM, Guillou PJ, Coletta PL, Hull MA. 2003. Expression of macrophage migration inhibitory factor in human sporadic colorectal adenomas. BRIT J SURG.
Wilson JM, Scott N, Guillou PJ, Markham AF, Coletta PL, Hull MA. 2003. Expression of macrophage migration inhibitory factor in intestinal adenomas. GUT.
Hawcroft G, Gardner SH, Hull MA. 2003. The role of PPAR gamma in the anti-colorectal cancer activity of indomethacin. GUT.
Wilson JM, Scott N, Guillou PJ, Markham AF, Coletta PL, Hull MA. 2003. Expression of macrophage migration inhibitory factor in intestinal adenomas. Gut.
Presentation (conference/workshop etc)
Books
Chapters
Hull Mark A. 2008. Chapter 5. In: Bile Acids. Issues in Toxicology.
Hull MA, Hawkey CJ. 1998. Dyspepsia and Peptic Ulcer Disease. In: Drug Therapy in Old Age.
Conference abstracts
Koo S, Sharp L, McPherson S, Hull MA, Rushton S, Neilson L, OSCAR The Study team, Rees CJ. 2021. P38 High prevalence of liver disease and obesity amongst a colonoscopy population. Gut.
Koo S, Sharp L, Hull MA, Rushton S, Neilson L, Mcpherson S, OSCAR The Study team, Rees CJ. 2021. P40 Preliminary results of the obesity related colorectal adenoma risk (OSCAR) study. Gut.
Koo S, Masi A, Lamb CA, Hull MA, Sharp L, Nelson A, Hampton JS, Rees CJ, Stewart CJ. 2021. P304 Using Faecal Immunochemical Tests (FIT) for large-scale gut microbiota analysis. Gut.
Preprints
Sun Ge, Li Yan Ning, Davies John R, Block Robert, Kothapalli Kumar SD, Brenna J Thomas, Hull Mark A. 2023. FADS2 Indel polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid EPA. In: medRxiv.
Moon R, Moore JB, Hull MA, Zulyniak MA. 2022. Investigation of the association between high arachidonic acid synthesis and colorectal polyp incidence: a Mendelian randomisation approach. In: medRxiv.
Reports
Internet publications
Performances
Compositions
Exhibitions
Posters
Artefacts
Designs
Patents
Scholarly editions
Software / code
Thesis / dissertations
Others
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Supplementary Table 2 from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Supplementary Figure 2 from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Supplementary Table 1 from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Supplementary Figure 3 from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Data from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Aldoori Joanna, Zulyniak Michael A, Toogood Giles J, Hull Mark A. 2025. Supplementary Figure 1 from Plasma <i>n</i>-3 Polyunsaturated Fatty Acid Levels and Colorectal Cancer Risk in the UK Biobank: Evidence of Nonlinearity, as Well as Tumor Site- and Sex-Specificity.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Data from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies John R, Mell Tracey, Fuller Harriett, Harland Mark, Saleh Rasha NM, Race Amanda D, Rees Colin J, Brown Louise C, Loadman Paul M, Downing Amy, Minihane Anne Marie, Williams Elizabeth A, Hull Mark A. 2023. Table 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Datasets
Hull Mark. Measuring omega-3 fatty acid levels in terminal ileal content following four weeks of omega-3 fatty acid supplementation in patients with a temporary ileostomy.
Hull Mark. Comparison of omega-3 fatty acid supplement formulations..